Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
investigational drug |
| gptkbp:CASNumber |
1610765-74-4
|
| gptkbp:clinicalTrialPhase |
Phase III (terminated)
|
| gptkbp:developedBy |
gptkb:AbbVie
gptkb:Stemcentrx |
| gptkbp:hasComponent |
rovalpituzumab
tesirine |
| https://www.w3.org/2000/01/rdf-schema#label |
rovalpituzumab tesirine
|
| gptkbp:indication |
Small Cell Lung Cancer
|
| gptkbp:mechanismOfAction |
delivers cytotoxic agent to DLL3-expressing cells
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:status |
discontinued
|
| gptkbp:synonym |
gptkb:Rova-T
|
| gptkbp:target |
gptkb:DLL3
|
| gptkbp:UNII |
6Q1K1Y1K0F
|
| gptkbp:bfsParent |
gptkb:Rova-T
|
| gptkbp:bfsLayer |
8
|